S&K Biopharma

S&K Biopharma is a South Korean biotechnology company focused on the discovery and development of novel small molecule therapeutics for autoimmune diseases, inflammatory conditions, and oncology. The company utilizes a proprietary kinase inhibitor discovery platform to design highly selective candidates that aim to minimize off-target effects and improve safety profiles. Its lead program, SKB-101, is a selective Janus kinase inhibitor being developed for dermatological indications such as psoriasis and atopic dermatitis. S&K Biopharma is also advancing a pipeline of preclinical assets, including SKB-201 for rheumatoid arthritis and SKB-301 for various solid tumors. By focusing on high selectivity, the company aims to overcome the safety limitations, such as cardiovascular risks, associated with earlier-generation kinase inhibitors. S&K Biopharma is headquartered in the Pangyo Techno Valley, a major biotech hub in South Korea.